drugset
drugset / Trial / NCT03093428

Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC

NCT03093428 ↗

Phase 2 Completed 45 enrolled Dana-Farber Cancer Institute Merck Sharp & Dohme LLC · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

This research study is studying the safety and tolerability of an investigational combination of drugs, radium-223 plus pembrolizumab as a possible treatment for castration-resistant prostate cancer. The interventions involved in this study are: * Radium-223 * Pembrolizumab

Timeline

Start
2017-06-09
Primary completion
2020-04-09
Completion
2025-02-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Pembrolizumab Monoclonal antibody — Intravenous
Subject Radium-223 dichloride Other / unclassified — Intravenous

Indications

prostate cancer